Orbimed advisors buys Adicet Bio (ACET) shares worth $5 million

OrbiMed Advisors LLC, along with several affiliated entities, reported purchasing shares of Adicet Bio, Inc. (NASDAQ:ACET) on October 8, 2025. The transactions involved the acquisition of 5,000,000 shares at a price of $1.00 per share, totaling $5,000,000. The stock currently trades at $0.97, near its 52-week low, with InvestingPro data showing a price-to-book ratio of 0.57x, suggesting potential undervaluation.

The shares were acquired through two separate transactions. 1,500,000 shares were purchased by OrbiMed Private Investments V, LP, while 3,500,000 shares were bought by OrbiMed Private Investments VI, LP.

Following these transactions, OrbiMed Private Investments V, LP holds 9,026,359 shares, OrbiMed Private Investments VI, LP holds 4,490,254 shares, OrbiMed Israel Partners Limited Partnership holds 1,027,885 shares, OrbiMed Israel Partners II, L.P. holds 646,657 shares and OrbiMed Genesis Master Fund, L.P. holds 1,255,985 shares of Adicet Bio, Inc.

OrbiMed Advisors LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd. and OrbiMed Israel BioFund GP Limited Partnership may be deemed to have beneficial ownership over the reported shares. For comprehensive analysis of Adicet Bio’s ownership structure and financial metrics, access the full company research report on InvestingPro. Each of these entities disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

In other recent news, Adicet Bio, Inc. announced promising preliminary results from its ADI-001 therapy for lupus patients, with 60% of participants achieving a complete renal response. The data showed that all seven patients in the study experienced rapid systemic disease control and a favorable safety profile, leading Guggenheim to raise its price target for the company to $8.00 while maintaining a Buy rating. Meanwhile, Citizens reiterated its Market Perform rating, maintaining a neutral stance on the stock. Additionally, Adicet Bio priced an $80 million stock offering at $1 per share, aiming to raise funds through the sale of common stock and pre-funded warrants. The company expects to generate approximately $80 million in gross proceeds before accounting for expenses. These developments highlight the company’s ongoing efforts in advancing its allogeneic gamma delta T cell therapies for autoimmune diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.